Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences
Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences: A Pilot Study
University Hospital, Basel, Switzerland
10 participants
Jul 18, 2022
INTERVENTIONAL
Conditions
Summary
This study is to evaluate the sensitivity and intra-/inter-observer agreement of the averaged magnetization inversion recovery acquisitions (AMIRA) in spinal cord (SC) Multiple sclerosis (MS) lesion detection and to evaluate the additional clinical value of this sequence in clinical settings.
Eligibility
Inclusion Criteria3
- Diagnosis of multiple sclerosis according to established international criteria
- Steroid free period: \> 4 weeks
- Participation in the Swiss MS Cohort (SMSC) study
Exclusion Criteria6
- History of severe (other) neurological, internal or psychiatric disease with SC affection
- Paramagnetic and/or superparamagnetic foreign objects in the body (especially when located close to the SC)
- Pacemaker
- Claustrophobia
- Pregnancy, lactation
- Known hypersensitivity to gadolinium-based contrast media
Interventions
SC MRI (Averaged Magnetization Inversion Recovery Acquisitions (AMIRA), standard conventional SC MRI sequences, additional sequences for spinal cord MRI (sagittal-2D or 3D short tau inversion recovery, sagittal-2D or 3D phase-sensitive inversion recovery, 3D magnetization prepared 2 rapid acquisition gradient echoes (MPRAGE)). To evaluate the presences of ongoing inflammation (acute or chronic) in the SC of patients, 3D MPRAGE and 3D fluid-attenuated inversion recovery images after intravenous gadolinium (Gd) contrast administration (0.1 mmol per kg body weight) will be acquired.
12-item multiple sclerosis walking scale (MSWS-12) questionnaire: self-report measure of the impact of MS on the individual's walking ability
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04819737